Trials / Completed
CompletedNCT00435916
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-40 | 1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2007-02-16
- Last updated
- 2015-01-07
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00435916. Inclusion in this directory is not an endorsement.